Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?

ABSTRACT: In spite of tremendous advances in advanced ovarian cancer management through the past decade, notably owing to surgical expertise and novel combination molecules (including bevacizumab and PARP inhibitors), the optimal initial sequential strategy remains a major concern. Indeed, following seminal clinical trials, primary cytoreductive surgery (PCS) followed by adjuvant systemic therapy and interval cytoreductive surgery (ICS) following neoadjuvant chemotherapy (NACT) have been positioned as validated alternatives with distinct pros and cons, although a definite response is still unassessed. In clinical practice, decisions between PCS and ICS rely on multilayer parameters: the tumor itself, the patient, and the health structure. In this state-of-the-art review, we will discuss the current

SUBMITTER: Quesada S 

PROVIDER: S-EPMC10377152 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature